Anika Historical Financial Ratios

ANIK Stock

USD 16.31 0.02 0.12%

Anika Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.73 or Days Sales Outstanding of 54.36 will help investors to properly organize and evaluate Anika Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

About Anika Financial Ratios Analysis

Anika TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Anika Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Anika financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Anika Therapeutics history.

Anika Therapeutics Financial Ratios Chart

At this time, Anika Therapeutics' EV To Sales is quite stable compared to the past year. Inventory Turnover is expected to rise to 1.48 this year, although the value of Operating Cash Flow Per Share is projected to rise to (0.12).

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Book Value Per Share Dividend Paid And Capex Coverage Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Anika Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Anika Therapeutics sales, a figure that is much harder to manipulate than other Anika Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most ratios from Anika Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' EV To Sales is quite stable compared to the past year. Inventory Turnover is expected to rise to 1.48 this year, although the value of Operating Cash Flow Per Share is projected to rise to (0.12).

	2021	2022	2023	2024 (projected)
Days Sales Outstanding	73.7	80.9	78.76	54.36
PTB Ratio	1.8	1.51	1.56	1.73

Days Sales Outstanding Ptb Ratio

Anika Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.89	-0.12	0.19	0.13	0.74	-0.36	0.36	0.89	0.98	0.67	0.56	-0.49	0.6	0.28	-0.01	0.37	0.07	0.6	0.31	0.17	0.26	0.33	0.1	0.29	0.52
Ptb Ratio	0.89		0.03	0.14	0.33	0.69	-0.21	0.09	1.0	0.94	0.66	0.58	-0.27	0.52	-0.02	0.24	0.42	-0.2	0.44	0.24	0.37	0.29	0.29	-0.17	0.24	0.56
Days Sales Outstanding	-0.12	0.03		-0.1	0.56	0.12	0.46	-0.14	0.03	-0.02	0.11	0.47	0.72	0.33	-0.75	0.17	-0.07	-0.4	-0.02	0.29	0.34	0.5	0.11	-0.4	0.23	0.49
Book Value Per Share	0.19	0.14	-0.1		0.37	0.29	-0.27	-0.36	0.14	0.3	0.24	0.0	-0.36	-0.04	-0.08	0.07	0.9	-0.56	0.72	0.19	-0.46	0.41	0.1	-0.42	0.05	0.06
Free Cash Flow Yield	0.13	0.33	0.56	0.37		0.62	0.42	-0.59	0.33	0.27	0.68	0.64	0.52	0.43	-0.82	0.5	0.52	-0.87	0.46	0.28	0.13	0.62	0.2	-0.7	0.45	0.67
Operating Cash Flow Per Share	0.74	0.69	0.12	0.29	0.62		-0.07	0.02	0.69	0.75	0.98	0.81	-0.1	0.79	-0.15	0.27	0.48	-0.29	0.8	0.41	0.01	0.51	0.29	-0.19	0.59	0.8
Average Payables	-0.36	-0.21	0.46	-0.27	0.42	-0.07		-0.33	-0.21	-0.3	0.01	0.2	0.79	0.07	-0.64	0.02	-0.25	-0.34	-0.29	0.05	0.36	0.18	0.02	-0.23	0.17	0.21
Capex To Depreciation	0.36	0.09	-0.14	-0.36	-0.59	0.02	-0.33		0.09	0.22	-0.14	0.04	-0.43	0.25	0.66	-0.42	-0.33	0.83	0.0	0.06	-0.2	-0.19	0.09	0.69	-0.02	-0.01
Pb Ratio	0.89	1.0	0.03	0.14	0.33	0.69	-0.21	0.09		0.94	0.66	0.58	-0.27	0.52	-0.02	0.24	0.42	-0.2	0.44	0.24	0.37	0.29	0.29	-0.17	0.24	0.56
Ev To Sales	0.98	0.94	-0.02	0.3	0.27	0.75	-0.3	0.22	0.94		0.69	0.59	-0.42	0.58	0.13	0.06	0.48	-0.1	0.64	0.34	0.21	0.35	0.34	-0.06	0.29	0.56
Free Cash Flow Per Share	0.67	0.66	0.11	0.24	0.68	0.98	0.01	-0.14	0.66	0.69		0.81	0.0	0.76	-0.23	0.34	0.41	-0.36	0.72	0.4	0.11	0.49	0.28	-0.26	0.6	0.79
Roic	0.56	0.58	0.47	0.0	0.64	0.81	0.2	0.04	0.58	0.59	0.81		0.3	0.94	-0.42	0.39	0.18	-0.24	0.46	0.72	0.24	0.77	0.31	-0.28	0.53	0.98
Inventory Turnover	-0.49	-0.27	0.72	-0.36	0.52	-0.1	0.79	-0.43	-0.27	-0.42	0.0	0.3		0.16	-0.85	0.34	-0.34	-0.41	-0.4	0.14	0.38	0.29	0.07	-0.42	0.23	0.34
Net Income Per Share	0.6	0.52	0.33	-0.04	0.43	0.79	0.07	0.25	0.52	0.58	0.76	0.94	0.16		-0.21	0.28	0.08	0.0	0.48	0.75	0.15	0.7	0.42	-0.1	0.66	0.95
Days Of Inventory On Hand	0.28	-0.02	-0.75	-0.08	-0.82	-0.15	-0.64	0.66	-0.02	0.13	-0.23	-0.42	-0.85	-0.21		-0.52	-0.17	0.79	0.05	-0.22	-0.32	-0.53	-0.14	0.73	-0.31	-0.48
Payables Turnover	-0.01	0.24	0.17	0.07	0.5	0.27	0.02	-0.42	0.24	0.06	0.34	0.39	0.34	0.28	-0.52		0.25	-0.46	0.09	0.16	-0.01	0.31	0.17	-0.79	0.2	0.42
Average Inventory	0.37	0.42	-0.07	0.9	0.52	0.48	-0.25	-0.33	0.42	0.48	0.41	0.18	-0.34	0.08	-0.17	0.25		-0.65	0.73	0.14	-0.36	0.43	0.11	-0.47	0.11	0.22
Capex To Revenue	0.07	-0.2	-0.4	-0.56	-0.87	-0.29	-0.34	0.83	-0.2	-0.1	-0.36	-0.24	-0.41	0.0	0.79	-0.46	-0.65		-0.32	-0.04	-0.08	-0.43	-0.05	0.8	-0.16	-0.29
Cash Per Share	0.6	0.44	-0.02	0.72	0.46	0.8	-0.29	0.0	0.44	0.64	0.72	0.46	-0.4	0.48	0.05	0.09	0.73	-0.32		0.31	-0.37	0.45	0.23	-0.22	0.42	0.47
Pocfratio	0.31	0.24	0.29	0.19	0.28	0.41	0.05	0.06	0.24	0.34	0.4	0.72	0.14	0.75	-0.22	0.16	0.14	-0.04	0.31		0.08	0.89	0.29	-0.17	0.3	0.74
Interest Coverage	0.17	0.37	0.34	-0.46	0.13	0.01	0.36	-0.2	0.37	0.21	0.11	0.24	0.38	0.15	-0.32	-0.01	-0.36	-0.08	-0.37	0.08		0.04	0.02	-0.08	0.16	0.22
Capex To Operating Cash Flow	0.26	0.29	0.5	0.41	0.62	0.51	0.18	-0.19	0.29	0.35	0.49	0.77	0.29	0.7	-0.53	0.31	0.43	-0.43	0.45	0.89	0.04		0.22	-0.46	0.35	0.8
Pfcf Ratio	0.33	0.29	0.11	0.1	0.2	0.29	0.02	0.09	0.29	0.34	0.28	0.31	0.07	0.42	-0.14	0.17	0.11	-0.05	0.23	0.29	0.02	0.22		-0.15	0.59	0.4
Days Payables Outstanding	0.1	-0.17	-0.4	-0.42	-0.7	-0.19	-0.23	0.69	-0.17	-0.06	-0.26	-0.28	-0.42	-0.1	0.73	-0.79	-0.47	0.8	-0.22	-0.17	-0.08	-0.46	-0.15		-0.16	-0.34
Income Quality	0.29	0.24	0.23	0.05	0.45	0.59	0.17	-0.02	0.24	0.29	0.6	0.53	0.23	0.66	-0.31	0.2	0.11	-0.16	0.42	0.3	0.16	0.35	0.59	-0.16		0.63
Roe	0.52	0.56	0.49	0.06	0.67	0.8	0.21	-0.01	0.56	0.56	0.79	0.98	0.34	0.95	-0.48	0.42	0.22	-0.29	0.47	0.74	0.22	0.8	0.4	-0.34	0.63

Click cells to compare fundamentals

Anika Therapeutics Account Relationship Matchups

Anika Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	6.39	4.93	3.49	2.76	1.99	3.33
Ptb Ratio	2.54	2.36	1.8	1.51	1.56	1.73
Days Sales Outstanding	73.5	67.43	73.7	80.9	78.76	54.36
Book Value Per Share	20.42	19.15	19.94	19.61	14.48	15.21
Free Cash Flow Yield	0.0467	0.0178	0.006306	(0.007139)	(0.0217)	(0.0228)
Stock Based Compensation To Revenue	0.0531	0.0413	0.075	0.0916	0.0915	0.0869
Capex To Depreciation	0.79	0.47	0.12	0.36	0.52	0.38
Pb Ratio	2.54	2.36	1.8	1.51	1.56	1.73
Ev To Sales	3.75	5.2	4.36	2.98	2.4	1.73
Free Cash Flow Per Share	2.42	0.8	0.23	(0.21)	(0.49)	(0.47)
Roic	0.0894	(0.0445)	(0.11)	(0.0538)	(0.4)	(0.38)
Inventory Turnover	1.31	1.33	1.8	1.58	1.37	1.48
Net Income Per Share	1.93	(1.69)	0.29	(1.02)	(5.64)	(5.36)
Days Of Inventory On Hand	279.27	274.56	202.67	231.63	266.32	285.53
Payables Turnover	7.5	6.84	8.5	6.91	6.45	6.22
Capex To Revenue	0.0247	0.0125	0.0348	0.0479	0.0326	0.0309
Cash Per Share	13.1	6.91	6.55	5.93	4.97	3.5
Pocfratio	19.79	49.27	61.45	97.76	(185.74)	(176.45)
Capex To Operating Cash Flow	0.0764	0.12	0.61	1.7	(3.04)	(2.88)
Pfcf Ratio	21.42	56.28	158.57	(140.07)	(46.03)	(43.73)
Days Payables Outstanding	48.65	53.38	42.96	52.86	56.61	80.78
Income Quality	1.36	(0.54)	2.03	(0.3)	0.0216	0.0205
Roe	0.0943	(0.088)	0.0144	(0.052)	(0.39)	(0.37)
Ev To Operating Cash Flow	16.11	43.53	52.5	85.18	(161.23)	(153.17)
Pe Ratio	26.93	(26.84)	124.82	(29.01)	(4.02)	(3.82)
Return On Tangible Assets	0.0862	(0.0901)	0.0161	(0.0556)	(0.32)	(0.3)
Ev To Free Cash Flow	17.44	49.73	135.48	(122.06)	(39.95)	(37.96)
Earnings Yield	0.0371	(0.0373)	0.008012	(0.0345)	(0.25)	(0.24)
Intangibles To Total Assets	0.0462	0.27	0.26	0.23	0.0451	0.0428
Net Debt To E B I T D A	(3.97)	5.84	(28.74)	11.28	3.9	4.1
Current Ratio	14.48	4.81	5.66	6.07	5.26	7.0
Tangible Book Value Per Share	19.34	12.15	13.67	13.98	13.65	14.33
Receivables Turnover	4.97	5.41	4.95	4.51	4.63	7.3
Graham Number	29.75	26.96	11.35	21.22	42.87	45.02

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:

How To Invest In Anika

Details

Is Anika Stock a good investment?

Details

What is Anika Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.51)

Earnings Share

(6.64)

Revenue Per Share

11.139

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.04)

The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Anika Historical Financial Ratios

About Anika Financial Ratios Analysis

Anika Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Book Value Per Share

Anika Therapeutics fundamentals Correlations

Anika Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anika Therapeutics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Ev To Sales	+ 0.98	Price To Sales Ratio
Free Cash Flow Per Share	+ 0.98	Operating Cash Flow Per Share
Roe	+ 0.98	Roic
Roe	+ 0.95	Net Income Per Share
Ev To Sales	+ 0.94	Ptb Ratio

Capex To Revenue	- 0.87	Free Cash Flow Yield
Days Of Inventory On Hand	- 0.85	Inventory Turnover
Days Of Inventory On Hand	- 0.82	Free Cash Flow Yield
Days Payables Outstanding	- 0.79	Payables Turnover
Days Of Inventory On Hand	- 0.75	Days Sales Outstanding
Days Payables Outstanding	- 0.7	Free Cash Flow Yield